Monoclonal antibodyFDA-approvedSecond-line
Zaltrap
Generic name: aflibercept
How it works
Aflibercept blocks the vascular endothelial growth factor (VEGF) and placental growth factor (PlGF), proteins that promote blood vessel growth and support tumor growth.
Cancer types
Colorectal Cancer— All patients
Efficacy
In clinical trials, Zaltrap improved overall survival in patients with metastatic colorectal cancer, with a median survival benefit of around 1.4 months.
Side effects
Severe
This treatment carries a higher risk of serious side effects. Close medical monitoring is required throughout treatment.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Aflibercept plus chemotherapy in metastatic colorectal cancer | Colorectal Cancer | meta-analysis | The pooled estimate rates were 16.0% for 12mPFS, 64.4% for 12mOS, 32.5% for ORR, 83.5% for DCR. | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.